Morgan Stanley's checks indicates DRAM and NAND spot prices have fallen sharply over the past two weeks and that the market is mis-reading memory price trends given current supply discipline. The analyst expects NAND profitability to be much lower than current expectations and believes pricing faces steep declines ahead. DRAM has slight upside, but only limited, and pricing is expected to be weak in March, according to the analyst.
Google "CNBC video=3000250004" and you can view the video explaining why BBRY will be at 15 soon.
Shorts, no need to watch this. It will only mess up your weekend.
And lots of shorts out there will get it to more than double.
Wow, lots of shorts troll this board. Carter talk will probably get BBRY near 11 on Monday.
buy low, sell high, trend is your friend, etc...sometimes you just have to go with the flow....bbry 15 soon...if not more.
I'm in the 20+ camp.
Jefferies analyst Thomas Wei commented on Avanir Pharmaceuticals (NASDAQ: AVNR), saying although the company is likely to win its patent trial upside is limited. Therefore, a Hold rating and $4 target was maintained.
"Based on our review of 1,250 pages of court transcripts, we believe the odds are in AVNR's favor to win its Nuedexta patent trial against Par/Impax," Wei notes. "Although the stock may react favorably to a win, our valuation already credits AVNR for the full patent life for Nuedexta and a second-generation Nuedexta and continued linear demand growth through 2016 to reach a $4 price target and Hold rating.
7:55a ET February 24, 2014 (Benzinga)
In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Agenus (NASDAQ: AGEN) with a Buy rating and $8.00 price target.
In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Agenus with a BUY rating and a target price of $8. In our opinion, the acquisition of 4-Antibody has propelled the company into the ever exciting field of checkpoint inhibitors. With the addition of 6 lead checkpoint programs, we believe Agenus could soon find itself in the cross hairs of other Pharma/Biotech acquirers. In addition, the company's proprietary personalized platform technology encompassing cancer and infectious disease vaccines as well as the partnered QS-21 program represent significant value drivers for investors.
"With a portfolio of diverse assets, a confluence of milestones anticipated over the next 12-18 months, and a cash position of $85 MM (proforma), we believe Agenus represents an undervalued player with significant upside for the long-term investor.”